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Abstract 
Background: The mucin MUC16 expresses the repeating peptide epitope CA125 that has 
been known for decades to be a well-validated cancer marker that is overexpressed on the 
cell surface of ovarian cancers and other malignant tumors. In spite of recent efforts to make 
mouse monoclonal antibodies to MUC16 to treat ovarian cancer, a human monoclonal an-
tibody against this mucin has not been described. MUC16 interacts with mesothelin, a protein 
that mediates heterotypic cancer cell adhesion, indicating that MUC16 and mesothelin play an 
important role in the peritoneal implantation and metastasis of ovarian tumors. Therefore, a 
suitable candidate for therapeutic targeting of MUC16 would functionally block the interac-
tion of MUC16 and mesothelin.  
Methodology/Principal Findings: Here we report the generation of a novel immunoadhesin, 
HN125, against MUC16 that consists of a functional MUC16 binding domain of mesothelin 
(IAB) and the Fc portion of a human antibody IgG1. The yield for purified HN125 proteins is 
over 100 µg/mL of HEK-293 culture supernatant. We show that HN125 has high and specific 
affinity for MUC16-expressing cancer cells by flow cytometry and immunohistochemistry. 
HN125 has the ability to disrupt the heterotypic cancer cell adhesion mediated by the 
MUC16-mesothelin interaction. Moreover, it elicits strong antibody-dependent cell mediated 
cytotoxicity against MUC16-positive cancer cells in vitro.  
Conclusion/Significance: This report describes a novel human immunotherapeutic agent highly 
specific for MUC16 with potential for treating ovarian cancer and other MUC16-expressing 
tumors. Because of its lower immunogenicity in patients, a fully human protein is the most 
desirable format for clinical applications. We believe that the methods developed here may 
apply to the generation of other tumor-targeting immunoadhesins when it is difficult to obtain 
a human monoclonal antibody to a given antigen for clinical applications. The resultant im-
munoadhesins can have advantages usually found in monoclonal antibodies such as ease of 
purification, high binding affinity and effector functions. 
Key  words:  immunoadhesin,  human  Fc  fusion,  mesothelin,  mucin  MUC16/CA125,  anti-
body-dependent cellular cytotoxicity (ADCC), ovarian cancer, mesothelioma. 
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INTRODUCTION 
Epithelial ovarian cancer is the most lethal gy-
necologic malignancy in the United States, resulting 
in an estimated 21,880 new cases and 13,850 deaths in 
2010 [1, 2]. The high mortality rate is due to the lack of 
effective screening methods and the high incidence of 
chemotherapy  resistance.  Targeted  immunotherapy 
with  monoclonal  antibodies  (mAbs)  has  become  a 
promising strategy for cancer treatment. A mAb can 
selectively  target  tumor  cells  that  express  tu-
mor-specific  antigens  but  not  normal  healthy  cells. 
Novel mAbs have become one of the biggest classes of 
new drugs approved for the treatment of cancer, in-
cluding ovarian cancer. Hundreds of mAbs, as well as 
novel Fc fusion proteins that are composed of binding 
peptides or proteins fused to the Fc domain of im-
munoglobulin G, are undergoing clinical study [3]. By 
the end of 2010, a total of 30 of these candidates (25 
mAbs and 5 Fc fusion proteins) were in Phase 2/3 or 
Phase 3 clinical studies [3]. Many therapeutic mAbs 
against vascular endothelial growth factor (VEGF) or 
VEGF receptor (VEGFR) [4-6], epidermal growth fac-
tor  receptors  [7,  8],  and  human  epidermal  growth 
factor receptor-2 [9-13] are being developed for ovar-
ian  cancer  therapy.  Farletuzumab  is  a  humanized 
IgG1 mAb that targets human folate receptor , which 
is highly expressed in most epithelial ovarian cancers 
[3]. The Phase 3 study of farletuzumab in combination 
with carboplatin and abraxane in ovarian cancer pa-
tients is currently recruiting participants.  
CA125  is  a  repeating  peptide  epitope  of  the 
membrane-spanning mucin MUC16, which is highly 
expressed on the cell surface of ovarian cancer cells, 
mesotheliomas and other malignant tumors. In addi-
tion to malignant tissues, MUC16 is also expressed in 
normal  epithelia  of  the  endometrium,  trachea,  and 
cornea [14-16]. In normal tissues MUC16 is believed to 
contribute to fetal development, acts as a barrier to 
trophoblast  adherence  and  bacterial  infection  and, 
through  its  interactions  with  cytoskeletal  proteins, 
plays  a  role  in  the  formation  of  microplicae  in  the 
corneal epithelium [15-19]. In ovarian tumors, MUC16 
plays  an  important  immunosuppressive  role  by 
blocking the cytotoxicity of natural killer (NK) cells 
and also by facilitating peritoneal metastasis of ma-
lignant ovarian cancer cells [20-24].  
Mesothelin  is  a  tumor  differentiation  antigen 
expressed at high levels in mesotheliomas, as well as 
ovarian, pancreatic and lung cancers [25-26]. Our re-
cent studies have indicated that mesothelin may be a 
potential  therapeutic  target  in  primary  liver  cancer, 
particularly  cholangiocarcinoma  [27].  MUC16  binds 
to  mesothelin  and  mediates  attachment  of  ovarian 
cancer  cells  to  the  peritoneal  walls  [23,  28-30].  The 
MUC16-mesothelin  interaction  mediates  cancer  cell 
adhesion [28, 30], indicating that the interaction may 
possibly play an important role in the implantation 
and spread of tumors. Furthermore, we have recently 
identified  that  a  functional  domain  in  mesothelin 
from residues 296 – 359, named IAB, is required and 
sufficient  to  bind  MUC16  [30].  Because  MUC16  is 
poorly internalized, immunoconjugates or drug con-
jugates that act inside the cells may be less effective. 
Efforts  have  focused  on  making  mouse  mAbs  to 
MUC16 that are currently being evaluated in clinical 
(mAb  B43.13  or  Oregovomab  or  OVARex®,  ViRexx 
Medical  Corp.,  Edmonton,  Canada)  [1,  31-33]  and 
preclinical studies (mAbs 11D10 and 3A5, Genentech, 
South  San  Francisco,  CA)  [34].  However,  a  human 
mAb against MUC16 has never been identified. Be-
cause of its lower immunogenicity in patients, a fully 
human protein is the most desirable format for clinical 
applications. We postulate that a more desirable mAb 
targeting MUC16-expressing tumors would be a hu-
man  IgG  that  can  functionally  block  the 
MUC16-mesothelin  interaction,  as  well  as  elicit  in-
ternalization-independent anti-tumor activity. 
In  recent  years,  human  IgG  Fc  fusion proteins 
have  emerged  as  a  credible  alternative  to  mAbs  in 
drug development [3, 35]. Most successful therapeutic 
antibodies or Fc fusion proteins target receptor and 
ligand  interactions.  Etanercept  (Enbrel)  is  the  first 
successful  example  of  using  a  soluble  receptor 
(TNFRII)-Fc fusion protein as a therapeutic drug. The 
US Food and Drug Administration has approved four 
Fc fusion proteins: Etanercept (Enbrel, TNFR), Ale-
facept  (Amevive,  LFA-3),  Abatacept  (Orencia,  hCT-
LA-4) and Rilonacept (Binding domains of IL-1R and 
IL-1RacP).  Many  more  Fc  fusion  proteins  are  cur-
rently being evaluated in clinical trials [3]. Aflibercept 
and  AMG  386,  two  Fc  fusion  proteins  designed  to 
interfere with tumor angiogenesis, are currently being 
evaluated in Phase 3 clinical studies to treat ovarian 
cancer. Aflibercept contains the extracellular domains 
of VEGFR1 and VEGFR2. AMG 386 is a “peptibody” 
composed of a peptide that binds angiopoietin-1 and 
-2 proteins.  
Here, we report the generation of a novel human 
Fc fusion immunoadhesin (named HN125) that con-
sists  of  IAB,  the  MUC16-binding  domain  of  meso-
thelin, fused to the N terminus of the Fc portion of a 
human antibody IgG1. We show that HN125 has high 
and  specific  affinity  for  MUC16-expressing  human 
ovarian  cancer  cells,  has  the  ability  to  significantly 
inhibit the MUC16-mesothelin interaction on cancer Journal of Cancer 2011, 2 
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cells, and elicits strong antibody-dependent cell me-
diated  cytotoxicity  against  cancer  cells.  Our  results 
indicate  that  HN125  has  therapeutic  potential  as  a 
novel  agent  for  treating  ovarian  cancer  and  other 
MUC16-expressing malignant tumors. This is the first 
report  of  a  human  immunotherapeutic  agent  that 
binds MUC16-expressing cancer cells and kills them 
without the aid of radioisotopes or cytotoxic drugs.  
MATERIAL AND METHODS 
Cell Culture 
A431/H9 is an A431 human epithelial carcinoma 
cell line that has been genetically engineered in our 
lab to over-express human mesothelin [36]. A431/H9 
cells  were  grown  in  DMEM  with  10%  fetal  bovine 
serum (FBS) (Hyclone, Thermo Scientific, Pittsburgh, 
PA), 1% L-glutamine, 1% penicillin, 1% streptomycin 
(Invitrogen,  Carlsbad,  CA)  and  G418  (700  μg/mL) 
(Invitrogen). ECC-1 is an endometrial cancer cell line 
and OVCAR3 is an epithelial ovarian tumor cell line, 
and both were purchased from ATCC (Manasas, VA). 
OVCAR3 (ovarian) cells were grown in DMEM with 
10% FBS, 1% L-glutamine, 1% penicillin, 1% strepto-
mycin  (Invitrogen)  and  with  human  insulin  (10 
μg/mL) (Eli Lilly, Indianapolis,  IN). NCI-H226 and 
YOU (mesothelioma) cells were grown in RPMI 1640 
(Invitrogen) supplemented with 10% FBS (Hyclone), 
1%  penicillin/streptomycin,  and  1%  l-glutamine 
(Invitrogen). ECC-1 cells were cultured in RPMI 1640 
media  (Invitrogen)  containing 10%  fetal  calf  serum. 
Cells were confirmed to be negative for mycoplasma. 
Construction of Expression Plasmid 
PCR amplification of IAB from pMH118 [30] was 
performed  using  primers  IAB-F(EcoRI): 
5’-GAATTCGATATCGGAAGTGGAGAAGACAGC
CTGTCCT-3’  and  IAB-R(BglII):  5’-AGATCTGAGC 
TCATCCAGTTTATGCTTTAGG-3’. The PCR product 
was purified and digested with EcoRI and BglII (New 
England  Biolabs,  Ipswich,  MA),  then  ligated  with 
pFUSE-hIgG1-Fc2 (Invivogen, San Diego, CA) linear-
ized with EcoRI and BglII. The resultant vector was 
reamplified for the IAB-hFc (Fc portion of a human 
antibody  IgG1)  part  using  primers  IL2-F: 
5’-TCGACACGTGTGATCAGATAGGGCCACCATG
TACAGGATGCAACTCCTGTCT-3’  and  hFc-R:  5’- 
TCTAGAGCGGCCGCGATACTCATTTACCCGGAG
ACAGGGAGAG-3’, The IAB-hFc PCR fragment was 
then digested with PmI and NotI, and inserted into the 
vector pVRC8400 [37, 38]. The final plasmid is named 
pMH142 (Figure 1A).  
 
 
 
 
 
 
Figure 1. Generation of immunoadhesin HN125. A. Dia-
gram of expression plasmid pMH142 for HN125 expression 
in human HEK-293F cells as NH2-terminal fusions to human 
IgG1  Fc  (hFc)  (Hinge-CH2-CH3).  CMV  IE  Enhanc-
er/Promoter:  human  cytomegalovirus  immediate-early 
enhancer/promoter; IL2 Sig: IL2 signal peptide; Tbgh: poly A 
bovine growth hormone tail; ori: origin of replication; Kan.: 
kanamycin resistance. B. The structural model of HN125. 
IAB  is  the  functional  binding  domain  in  mesothelin  for 
MUC16. CH2 and CH3: second and third constant domains 
of a human IgG1, respectively. C. SDS-PAGE analysis of 
HN125. Molecular weights: non-reduced dimers (~75 kDa) 
and reduced monomers (~37 kDa). 
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Expression and Purification of HN125 
Using 293fectin, 30 μg of pMH142 plasmid was 
transiently  transfected  into  3  x  107  HEK-293F  cells 
(Invitrogen) and kept in 30 mL of FreeStyle expression 
medium (Invitrogen) in a 125-mL spinner flask on a 
stirring platform at 75 rpm (CELLSPIN system; Inte-
gra, Chur, Switzerland) in a humidified atmosphere 
containing 8% CO2 at 37oC. After three days, the me-
dium was collected after centrifugation, replaced for 
an  additional  3-4  days,  and  collected  again.  Pooled 
supernatants were then processed and Fc fusion pro-
tein (HN125) was purified using a 1-mL recombinant 
Protein  A  Hi-Trap  column  (GE  Healthcare,  Pisca-
taway,  NJ)  on  an  AKTA  Explorer  Chromatography 
system (GE Healthcare) as described [39]. The quality 
and  quantity  of  HN125  were  determined  by 
SDS-PAGE  and  A280  absorbance  on  a  Nanodrop 
(Thermo Scientific/Nanodrop,  Wilmington,  DE),  re-
spectively.  
Structural Modeling of the HN125 Immunoad-
hesin 
The structural model of HN125 was generated 
by  molecular  modeling  using  I-TASSER  [40] 
(http://zhanglab.ccmb.med.umich.edu/I-TASSER). 
Molecular models were viewed and analyzed using 
VMD (http://www.ks.uiuc.edu/Research/vmd/) as 
described [41].  
Flow Cytometry and Binding Affinity 
OVCAR3  cells  were  used  as  MUC16-positive 
cells. A431/H9 cells were used as negative controls. 
To  detect  binding  between  HN125  and  target  cells, 
flow cytometry was performed on a FACSCalibur (BD 
Biosciences, San Jose, CA). First, 0.5-1 x 106 cells were 
incubated with 5 g/mL of HN125 for 1 hour. The 
binding  was  then  detected  with  a  1:200  goat  an-
ti-human  IgG  conjugated  with  Alexa488  (Sigma,  St 
Louis, MO) and incubated for 30 minutes. The bind-
ing affinity was determined using Prism (version 5) 
for Windows (GraphPad Software, La Jolla, CA).  
Immunohistochemistry 
Formalin-fixed  and  paraffin-embedded  tissue 
blocks from 15 patients with ovarian cancer were re-
trieved from the files of the Armed Forces Institute of 
Pathology. Consecutive sections at 5-7 m thickness 
were  prepared  and  placed  on  positively  charged 
slides.  Sections  were  deparaffinized  with 
three-changes of xylene, and washed with descending 
concentrations of alcohol and water, and subjected to 
antigen retrieval following our previously published 
protocol  [42].  Immunostaining  was  carried  out  as 
previously described [43] with HN125 and an isotype 
control  human  IgG (Southern Biotech, Birmingham, 
AL). The secondary antibody conjugated with perox-
idase,  diaminobenzidine  and 
3-amino-9-ethylcarbazole  chromogen  kits  were  ob-
tained from Vector Laboratories (Burlingame, CA). To 
assess the specificity of the immunostaining, different 
negative controls were used, including the substitu-
tion of the primary antibody with the same isotype or 
pre-immune serum of the antibody, and omission of 
the  secondary  antibody.  In  addition,  the  im-
munostaining procedure was repeated at least twice 
using the same protocol and under the same condi-
tions.  Immunostained  sections  were  independently 
evaluated by two investigators. A given cell was con-
sidered immunoreactive if distinct immunoreactivity 
was consistently seen in its cytoplasm, membrane, or 
nucleus,  while  all  negative  controls  lacked  distinct 
immunostaining. 
Heterotypic Cell Adhesion Assay  
OVCAR3 cells (1 x 105) were seeded in triplicate 
in 96-well plates and incubated overnight at 37°C, 5% 
CO2.  A431/H9  cells  were  trypsinized  the  next  day 
and labeled with CellTracker Red CMTPX Dye (Invi-
trogen) at a concentration of 5 μM for 15 minutes fol-
lowing  manufacturer’s  instructions.  The  OVCAR3 
monolayer cells were washed once with 200 L of 10% 
complete RPMI and incubated for 1 hour on ice with 
different concentrations of HN125 or CD30-hFc as a 
negative control. Labeled H9 cells (2 x 105) were then 
added  to  each  well  for  1  hour  on  ice.  Wells  were 
washed five times with 200 μL PBS by gently invert-
ing the plate on paper towels. Representative pictures 
of each well were taken using a Zeiss Axio Observer 
Z1  microscope  (Carl  Zeiss  MicroImaging,  Inc., 
Thornwood,  NY),  and  images  were  collected  with 
Axiovision software (Carl Zeiss MicroImaging, Inc.). 
The average intensity of fluorescence was measured 
using ImageJ software (National Institutes of Health, 
Bethesda, MD).  
Epitope Mapping 
To  map  the  mesothelin  binding  domain  on 
MUC16, two methods of flow cytometry were used. 
In the first method, FACS (FACS Calibur) was per-
formed by first incubating OVCAR3 cells (0.5-1 x 106) 
with  different  concentrations  of  the  mouse  mAbs 
OC125 (Invitrogen) and M11-like (Invitrogen) for 30 
minutes in 5% FACS buffer before HN125 was added 
at 0.1 µg/mL for 1 hour. The binding was then de-
tected with a 1:200 goat anti-mouse IgG conjugated 
with PE (Sigma) and incubated for 30 minutes. In the 
second method, FACS was performed by incubating 
OVCAR3 cells (0.5-1 x 106) with different concentra-Journal of Cancer 2011, 2 
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tions of HN125 before adding 0.1 µg/mL of OC125 
and  M11-like antibodies. The binding was  then de-
tected with a 1:200 goat anti-human IgG conjugated 
with FITC (Sigma). 
Antibody-dependent Cell Cytotoxicity Assay 
The  antibody-dependent  cell  cytotoxicity 
(ADCC) assay was performed on OVCAR3 cells using 
human peripheral blood mononuclear cells (PBMC). 
PBMC  (Department  of  Transfusion  Medicine,  NIH 
Clinical Center, Bethesda, MD) were isolated by di-
luting 15 mL of human buffy coat with equal volumes 
of PBS with 2 mM EDTA and serum free DMEM up to 
a total of 40 mL. Ten mL of the diluted buffy coat were 
then layered gently on 3 mL of Ficoll and centrifuged 
at  900xg  for  30  minutes  at  room  temperature.  The 
layer of PBMC was removed and diluted again to 4x 
volume with serum free DMEM before it was centri-
fuged  and  washed  twice  more  with  DMEM-all  at 
400xg  for  10  minutes  at  room  temperature.  PBMC 
were mixed with trypsinized OVCAR3 cells (1 x 104 
per well) at a ratio of 100:1. The mixture was incu-
bated  for  ~20  hours  at  standard  cell  culture  condi-
tions. A non-specific human IgG (Southern Biotech) 
was  used  as  a  negative  control.  The  viability  of 
OVCAR3 cells was measured using a  lactose dehy-
drogenase  (LDH)  detection  kit  (Roche  Applied  Sci-
ence, Branford, CT) per manufacturer’s instructions.  
ADCC Using Purified NK Cells  
NK cells were isolated from the peripheral blood 
of healthy donors using the RosetteSep Kit (StemCell 
Technologies, Vancouver, Canada). For the cytotoxi-
city assays, suspensions of OVCAR3 or ECC-1 cells 
were labeled with 51Cr. The target cells (1 x 105) were 
incubated with the NK cells at different effector:target 
concentrations in the presence or absence of human 
IgG or HN125. After incubation for 4 hours, the 51Cr 
released in the media  was measured and lysis per-
centage  was  measured  as  described  previously  [20, 
44].  
Statistical Analysis 
Statistical  analysis  was  performed  with  Prism 
(version 5) for Windows (GraphPad Software). Raw 
data  were  analyzed  by  “analysis  of  variance”  with 
Dunnett's  and  Newman-Keuls  multiple  comparison 
post tests. p values < 0.05 were considered statistically 
significant. 
Results 
Expression and Purification of HN125 
We have identified the IAB region, consisting of 
64  amino  acids  (EVEKTACPSGKKAREIDESLIFYK 
KWELEACVDAALLATQMDRVNAIPFTYEQLDVLK
HKLDEL)  at  the  N-terminal  of  cell  surface  mature 
mesothelin,  as  the  minimum  fragment  required  for 
complete binding activity to MUC16 [30]. In the pre-
sent  study,  we  constructed  a  hFc  protein  that  joins 
IAB, the functional binding domain for MUC16, with 
the  human  IgG1  Fc  fragment,  containing  CH2  and 
CH3 domains, at the hinge region (plasmid pMH142, 
Figure 1A). The hinge may serve as a flexible spacer 
between IAB and Fc, allowing each part of the mole-
cule  to  function  independently.  We  used  a  signal 
peptide  from  interleukin-2  (IL2).  The  predicted 
structure  of  this  hybrid  protein  (named  HN125)  is 
shown as a monomer in Figure 1B.  
HEK-293F cells were transfected with pMH142. 
Transfectants were first analyzed for secreted protein 
in the supernatant by ELISA. Since HN125 contained 
the human IgG1 Fc fragment, the Fc fusion protein in 
the supernatant was successfully purified in one step 
by  affinity  chromatography  using  protein  A  Se-
pharose. The purified HN125 was then analyzed by 
SDS-PAGE.  Because  the  Fc  region  of  human  IgG1 
introduced  into  the  Fc  fusion  protein  contained  a 
hinge region, HN125 is expected to form an internal 
S–S  linked  dimer.  HN125  showed  a  band  of  dimer 
size (~75 kDa) under non-reducing conditions, indi-
cating the dimeric properties of HN125 (Figure 1C). A 
single  band of monomer size (~37 kDa) was found 
under  reducing  conditions.  The  purity  was  above 
95%.  The yield  was over 100  g/mL of culture su-
pernatant.  
High Affinity Binding of HN125 on Cancer Cells 
The  binding  of  HN125  to  membrane-bound 
MUC16 on cancer cells was examined by flow cytom-
etry.  All  the  cancer  cell  lines  (A431/H9,  OVACR3, 
NCI-H226 and YOU) express mesothelin on the cell 
surface, while only OVCAR3 and YOU cells express 
MUC16  [30,  36,  39].  As  shown  in  Figure  2  (A-D), 
HN125  specifically  bound  to  the  MUC16-positive 
ovarian  cancer  cells  (OVCAR3)  and  mesothelioma 
cells (YOU), but not to the MUC16-negative A431/H9 
and NCI-H226 cancer cells, indicating excellent speci-
ficity  of  HN125  for  cancer  cell-associated  MUC16 
molecules. We have also tested the binding of HN125 
on additional four MUC16-negative cancer cell lines, 
no signal was found in any of these lines (data not 
shown). OVCAR3 cells showed a 600-fold increase in 
MUC16 detection. YOU cells had around ten-fold less 
MUC16 expression on the cell surface. Interestingly, 
HN125  showed  clear  and  strong  staining  on  YOU 
cells,  indicating  high  binding  affinity  of  HN125  for 
MUC16-positive cancer cells including those with low 
MUC16 expression. To measure the binding affinity of Journal of Cancer 2011, 2 
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HN125 on cancer cells, we made the binding satura-
tion curve and Scatchard Plot (Figure 2E and 2F). The 
Kd of HN125 on OVCAR3 cells was 13 nM.  
 A  human  micro-papillary  ovarian  tumor  was 
immunostained with HN125 (Figure 3). In the pres-
ence of HN125, strong and uniform cytoplasmic im-
munoreactivities were observed in a vast majority of 
the tumor cells, while weak and diffuse staining was 
occasionally found only in some individual or clusters 
of cells with the isotype control. The expression and 
subcellular localization of the MUC16 epitope recog-
nized by HN125 appeared to be correlated with tumor 
progression. Some cell clusters near the luminal face 
showed either no or nuclear immunostaining. Inter-
estingly, nearly all tumor cells in the basal-lateral face 
showed strong immunoreactivities with HN125. 
 
 
Figure 2. The binding of HN125 to MUC16 on cancer cells. A431/H9 (A), OVCAR3 (B), NCI-H226 (C) and YOU (D) cells 
were probed with HN125 (solid dark line). Dark gray shading: secondary antibody control. Each cell line and its GeoMean 
value: A431/H9 (6), OVCAR3 (1229), NCI-H226 (6) and YOU (137). GeoMean of the secondary antibody control was about 
6. The binding saturation curve (E) followed by Scatchard analysis (F) showed that the KD of HN125 to OVCAR3 cells was 
13 nM. Journal of Cancer 2011, 2 
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Figure  3.  Immunostaining  of  HN125  on  human  ovarian  tumors.  A  human  micro-papillary  ovarian  tumor  was  im-
munostained with HN125 (A-B; E-F) and an isotype human IgG control (C-D). Circles identify weak and diffuse staining 
occasionally found in some individual or clusters of cells with the isotype control. Squares in E and F show cells of the 
superficial layers (luminal face) with no, weak, or nuclear expression of the protein. Asterisks show cells of the deeper layers 
(baselateral face) with more intense and cytoplasmic expression of the protein. A, C, and E: 100X. B, D, and F: a higher 
magnification (400X) of A, C, and E, respectively. 
 
 
Mesothelin Binding Site on MUC16  
The well-characterized OC125 mAb was used to 
investigate the mesothelin binding domain on MUC16 
by flow cytometry. OC125 developed by Bast et al. 
reacts with CA125, an epitope of MUC16 present on 
the  surface  of  most  epithelial  ovarian  tumors  [45]. 
Figure 4 shows that when HN125 or full-length mes-
othelin was incubated with OVCAR3 cells first, the 
interaction between OC125 and MUC16 was reduced. 
The  difference  was  slightly  larger  using  full-length Journal of Cancer 2011, 2 
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mesothelin  than  using  HN125.  No  difference  was 
found  using  another  anti-CA125  mouse  mAb  M11 
(data not shown). The marginal inhibition observed 
with OC125 indicated that the HN125 binding epitope 
may  be  different  than  the  OC125  binding  epitope 
(CA125).  Previous  studies  indicated  that  the  meso-
thelin-binding site on CA125 is N-glycan dependent 
[23]. The precise binding site of mesothelin on MUC16 
remains elusive.  
Heterotypic Cell Adhesion Assay  
The  heterotypic  cell  adhesion  assay  was  per-
formed to determine if HN125 could inhibit the in-
teraction between cancer cells expressing MUC16 and 
those  expressing  mesothelin.  HN125  at  100  g/ml 
was  able  to  significantly  reduce,  by  approximately 
80%, the adherence of mesothelin-positive A431/H9 
cells  onto  the  MUC16-positive  OVCAR3  monolayer 
(Figure 5). At 10  g/mL, HN125 was able to block 
~50% of the heterotypic adhesion.  
 
 
 
 
 
Figure 4. Inhibition of the HN125 binding to MUC16 by 
OC125. OVCAR3 cells were probed with an anti-CA125 
mAb OC125 (solid dark line) or an irrelevant isotype mAb 
control (light gray shading). Cells were incubated with 0 (A, 
C) or 10 g/mL of full-length mesothelin (MSLN) (B) or 
HN125  (D)  before  OC125  was  added.  Their  GeoMean 
values: A, 480; B, 262; C, 410; D 287. GeoMean of the 
isotype antibody control was about 5.0. 
 
Figure 5. Inhibition of the MUC16-mesothelin mediated 
heterotypic cancer cell adherence. HN125 was examined in 
a  heterotypic  cell  adhesion  assay  using  OVCAR3  and 
A431/H9 cell lines. A. The mean intensity of each image was 
then analyzed using ImageJ software. The heterotypic cell 
adhesion between cells expressing mesothelin and MUC16 
was inhibited in the presence of 10 - 100 g/mL of HN125 
(p < 0.01). B. Microscopic images of cell adhesion assays in 
the presence of 100 μg/mL of HN125 or hFc control. hFc 
control: CD30-Fc. 
 
 
Anti-tumor Activity 
To  determine  if  the  human  IgG  Fc  domain  of 
HN125 was functionally able to direct ADCC toward 
antigen expressing target cells, we tested HN125 on 
OVCAR3  cells.  As  shown  in  Figure  6A,  using  the 
PBMC from healthy donors, HN125 exerted signifi-
cant  ADCC  activity  by  killing  about  35%  OVCAR3 
cells.  No  significant  lysis  of  the  targets  was  found Journal of Cancer 2011, 2 
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when the assays were conducted with a human IgG 
control.  When  tested  on  MUC16-negative  cells 
(A431/H9),  no  ADCC  activity  was  found.  We  also 
tested HN125 on YOU cells and significant but mod-
erate anti-tumor activity was found (data not shown).  
NK  cells  are  the  major  component  of  naïve 
PBMC  that  mediates  target  cell  lysis  via  ADCC. 
Therefore,  we  tested  the  HN125-mediated  lysis  of 
MUC16-expressing tumor target OVCAR3 cells and 
ECC-1 cells by NK cells isolated from the peripheral 
blood of two healthy donors. As shown in Figure 6B 
and  6C,  using  NK  cells  isolated  from  both  donors, 
HN125  can  elicit  dose-dependent  ADCC  activity  in 
both cell types, even OVCAR3 cells that are generally 
highly resistant to NK cell attack [23; Patankar et al. 
unpublished data]. Furthermore, the extent of lysis of 
OVCAR3 cells differs between NK cells isolated from 
different donors. Finally, we did not find significant 
complement-dependent cytotoxicity by HN125 (data 
not  shown),  suggesting  that  HN125  may  primarily 
mediate tumor target killing via ADCC. 
 
 
Figure  6.  HN125-mediated  killing  of  CA125-expressing 
cancer cells via ADCC. A. OVCAR3 cells were incubated 
with PBMC and either 10 μg/mL of HN125 or a control 
human IgG. Percent of cell death was measured using a LDH 
kit. About 35% of target cells were killed when treated with 
HN125 (p values < 0.05). B and C. NK cells isolated from 
peripheral blood of 2 healthy donors. OVCAR3 (B) and 
ECC-1 (C) cells used as targets were loaded with 
51Cr. Cell 
lysis was determined by the release of 
51Cr. Lysis assays 
were conducted in the presence or absence of HN125 as 
designated. Representative data shown is for effector:target 
ratio  of  12:1. Each E:T  was  tested  in  triplicate  in  three 
separate experiments. 
 
DISCUSSION 
Recent  studies  have  shown  that  MUC16  binds 
mesothelin  [28].  The  MUC16-mesothelin  interaction 
mediates cancer cell adhesion, indicating that MUC16 
and mesothelin may possibly play an important role 
in the implantation and metastatic spread of tumors. 
Therefore, there is an emerging interest to develop a 
drug to disrupt the interaction of MUC16 and meso-
thelin. In the present study, we report the develop-
ment  of  immunoadhesin  HN125,  a  functional  do-
main-Fc fusion protein, with great potential as a novel 
cancer therapeutic by disrupting the important bio-
logical interactions involving cancer pathogenesis or 
metastasis, and delivering effector cells specifically to 
the tumor cells that over-express MUC16 at the cell 
surface. HN125 is the first reported fully human im-
munotherapeutic  agent  specific  for  MUC16,  which 
has the potential for cancer treatment and diagnosis.  
 In principle, the efficacy of anti-cancer antibody 
therapy may be mainly determined by the number of 
antigens on the cell surface and the rate of antigen 
internalization. A recent study evaluated mAb 11D10 
for a non-repeating region of MUC16, and the anti-
body exhibited only partial activity against OVCAR3 
cells in vitro and in OVCAR3 xenograft models [34]. 
Interestingly,  the  same  research  group  found  mAb 
3A5  against  the  mucin  repeats  of  CA125,  and  that 
allowing multiple antibody bindings per CA125 mol-
ecule was more effective by increased binding of 3A5 Journal of Cancer 2011, 2 
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to cancer cells. Immunoconjugates or drug conjuates 
may enhance drug efficacy, however, due to its slow 
internalization,  MUC16  is  a  poor  target  for  the  im-
munoconjugates  or  drug  conjugates  that  act  inside 
cancer cells. 
 Several mouse mAbs have been developed and 
have been evaluated in clinical and preclinical studies 
[1]. In a randomized, double-blind, placebo-controlled 
trial  of  stage  III/IV  ovarian  cancer  patients  with  a 
complete  clinical  response,  Berek  et  al.  treated  145 
patients with oregovomab or a placebo [33]. The pri-
mary endpoint of the study was time to relapse (TTR), 
and  median  TTR  was  24  months  for  oregovomab 
compared to 11 months for the placebo. In a follow-up 
study 5 years after randomization, they also reported 
on  long-term  outcomes  for  this  patient  population 
[46].  Median  survival  was  58  months  for  patients 
given  oregovomab  compared  to  49  months  for  the 
placebo. In new preclinical studies, a drug conjugated 
mouse mAb 3A50 that targets CA125 repeats showed 
high efficacy in mouse models [34]. Due to low im-
munogenicity,  fully  human  proteins  are  highly  de-
sired for cancer therapy. No human mAb has been 
identified  to  date.  HN125  is  the  first  human  anti-
body-like immunoadhesin molecule targeting MUC16 
with therapeutic potential for treating ovarian cancer, 
mesothelioma and other MUC16-expressing tumors. 
It should be interesting to directly compare HN125 
with other anti-MUC16 antibodies and evaluate their 
anti-tumor activities in the future. 
 One concern about MUC16 as a therapeutic tar-
get is that soluble MUC16 in serum or in the perito-
neal  fluid  of  patients  may  inhibit  the  binding  of 
HN125.  Previous  studies  analyzed  more  than  30 
samples of ascites derived from individual epithelial 
ovarian cancer patients and found the concentration 
of MUC16 in this fluid ranges from 1 to 10 nM [23]. 
Since even 100 nM of soluble MUC16 did not inhibit 
the mesothelin-MUC16 interaction on cells, it is rea-
sonable to presume that soluble MUC16 in serum or 
peritoneal fluid would not neutralize HN125.  
 The mesothelin gene encodes a 71-kDa precur-
sor  protein  that  is  processed  to  a  40-kDa  mem-
brane-bound protein termed mesothelin and a 31-kDa 
shed  fragment  called  megakaryocyte-potentiating 
factor (MPF) that is released from the cell  [25]. We 
previously  generated  several  forms  of  recombinant 
mesothelin  proteins.  We  constructed  the  malt-
ose-binding protein (MBP)-mesothelin fusion expres-
sion  plasmid  (pMH103)  for  the  human  mesothelin 
expression in E. coli [36]. We also made the full-length 
mesothelin expression plasmid (pMH107) and gener-
ated the A431/H9 cell line stably expressing recom-
binant human mesothelin and MPF proteins [36]. In a 
recent  study,  we  constructed  the  rabbit  IgG 
Fc-mesothelin fusion expression plasmids for human 
mesothelin (pMH113 or pMH113b) and mouse mes-
othelin (pMH117) expression in human HEK-293 cells 
[30]. In all of these constructs, mesothelin was fused to 
the  C  terminus  of  a  native  (MPF)  or  recombinant 
(MBP and Fc) partner protein. To generate an effective 
immunoadhesin, it is essential to fuse the functional 
domain (IAB) of mesothelin to the N terminus of the 
hinge region followed by the human IgG Fc (CH2 and 
CH3 domains) which may mediate effector functions 
such as ADCC and CDC. The present study for the 
first time built a recombinant mesothelin protein at 
the N terminus of a fusion protein and the mesothelin 
retained its biological functions such as the MUC16 
binding.  Furthermore,  the  protein  production  yield 
was high (ranging from 100 to 500 μg/mL of HEK293 
culture supernatant), indicating our HEK-293 expres-
sion  method  is  feasible  for  large-scale  protein  pro-
duction of HN125 for preclinical and clinical studies.  
The present study used the cancer cells grown at 
the  monolayer  level  for  in  vitro  anti-tumor  activity 
assays such as cell adherence inhibition and ADCC. 
We and others have shown that cancer cells cultured 
as monolayers exhibit less resistance to therapy than 
those grown in vivo and may be explained by “multi-
cellular resistance”, a mechanism for drug resistance 
attributed  to  cell-cell  contacts,  cell-matrix  contacts, 
and the three-dimensional (3D) shape found in tumor 
tissue  [47].  Future  studies  utilizing  in  vitro  tumor 
spheroid models [47] and in vivo mouse models [48] 
are necessary to validate HN125 as a potential thera-
peutic agent for cancer therapy. 
 Our study reports HN125 as a novel immuno-
adhesin  against  tumor-associated  MUC16.  This  ap-
proach is novel because it does not depend on gener-
ations of human mAbs, but rather it uses a functional 
domain  involved  in  cancer  cell  adhesion.  Because 
HN125 is entirely of human origin and has high af-
finity for its target, it is expected to be less immuno-
genic than murine mAb and to be more efficient in 
targeting MUC16-expressing tumors. Consequently, it 
should be further evaluated as a potential therapeutic 
reagent for the treatment of ovarian cancer and other 
MUC16-expressing cancers. 
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